TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04125199

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: supplement consumption
Description: Composition of the Experimental Product: Concentrated oil of Tridocosahexaenoin-AOX® \* (350 mg per capsule), α-tocopherol and coating agent (gelatin). Each capsule is 700 mg, of which 500 mg is oil.~Placebo composition: Olive oil (each capsule is 700 mg).~Number of capsules: 6 per day, for any of the two products. The dose taken daily is 2.1 g / day for DHA.~Supplementation Period: Each group completed two 10-week consumption periods for each of the products, with an intermediate washing period of 4 weeks (28 days).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: supplement consumption
Description: Composition of the Experimental Product: Concentrated oil of Tridocosahexaenoin-AOX® \* (350 mg per capsule), α-tocopherol and coating agent (gelatin). Each capsule is 700 mg, of which 500 mg is oil.~Placebo composition: Olive oil (each capsule is 700 mg).~Number of capsules: 6 per day, for any of the two products. The dose taken daily is 2.1 g / day for DHA.~Supplementation Period: Each group completed two 10-week consumption periods for each of the products, with an intermediate washing period of 4 weeks (28 days).
Study: NCT04129242

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) + Task Specifc Training
Description: A closed-loop taVNS system that delivers taVNS with upper-limb rehabilitation training in a chronic stroke population.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) + Task Specifc Training
Description: A closed-loop taVNS system that delivers taVNS with upper-limb rehabilitation training in a chronic stroke population.
Study: NCT01845766

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise rehabilitation
Study: NCT00114257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: romidepsin
Study: NCT00397891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bapineuzumab
Description: The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bapineuzumab
Description: The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.
Study: NCT03103841

Intervention type: PROCEDURE
Intervention: Sleep studies [Polysomnography]
Description: Undertaking of sleep measurements by polysomnography and use of validated sleep questionnaires

Intervention type: PROCEDURE
Intervention: Sleep studies [Polysomnography]
Description: Undertaking of sleep measurements by polysomnography and use of validated sleep questionnaires
Study: NCT02159079

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservative Fluid Management Strategy
Description: For patients in the conservative fluid management arm, beginning 12 hours after admission to study ICU and ending at the first of ICU discharge, death, return to home inspired oxygen, or study day 14, fluid management will be controlled by a study protocol. Patients in shock will receive fluid boluses only as specified by the protocol for oliguria and rapidly increasing vasopressor requirement. Patients not in shock will receive fluid boluses only as specified by the protocol for oliguria. Output will exceed input each day using a diuretic drip if required. Study protocol will be held only for pre-specified Safety Endpoints of persistent oliguria, decompensating shock, diuretic side effect, and intervening acute event.
Study: NCT00085384

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-interferon alfa-2b
Description: Starting dose 1.0 mg/kg/week given subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-interferon alfa-2b
Description: Biological/Vaccine: PEG-interferon alfa-2b~Dose 1.25 mg/kg/week given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-interferon alfa-2b
Description: Biological/Vaccine: PEG-interferon alfa-2b~Dose 1.5 mg/kg/week given subcutaneously~EG-Intron
Study: NCT04936399

Intervention type: BIOLOGICAL
Intervention: Nivolumab
Description: Participants will receive Nivolumab after prior chemotherapy as part of an early access to medicines scheme (EAMS) program in the United Kingdom (UK)
Study: NCT03149757

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: YouTHrive
Description: The YT website is a mobile-enhanced private social networking website. Participants on the site are anonymous and choose alternate usernames and personalized profile features for a new online identity within YT. The investigators designed YouTHrive to encourage social support, reduce isolation, improve HIV medication adherence, and promote general well being. The study involves rolling recruitment so that new members are continuously entering the intervention. Participants use YT for five months before graduating from the program. The core components of YT are: 1) peer-to-peer interaction in a shared feed; 2) daily monitoring of HIV medication adherence and real-time mood; 3) daily mixed-media content with strategies to improve medication adherence' and 4) goal setting and monitoring.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information-only Control
Description: Participants will receive 21 emails, once per week, for five months. The emails will include static informational content relatable to YLWH, but informational content will not be focused on ART medication adherence.
Study: NCT04357080

Intervention type: PROCEDURE
Intervention: Urethroplasty
Description: Augmentation Anterior Urethroplasty Using Dorsal Onlay Buccal Mucosal Graft

Intervention type: PROCEDURE
Intervention: Urethroplasty
Description: Augmentation Anterior Urethroplasty Using Dorsal Onlay Buccal Mucosal Graft
Study: NCT01213277

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fast Glycator
Description: The subjects enrolled in this study will have a fructosamine test and blood drawn to see whether they are fast glycators

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: These patients will have their blood drawn to know what the normal glycation rate is in diabetic patients
Study: NCT00832156

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cultured autologous keratinocytes
Description: The experimental wound site will be covered with cultured keratinocytes on a collagen/elastin carrier after the application of a meshed split skin autograft. The control wound site will be covered with a meshed split skin autograft alone.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Cultured autologous keratinocytes
Description: The experimental wound site will be covered with cultured keratinocytes on a collagen/elastin carrier after the application of a meshed split skin autograft. The control wound site will be covered with a meshed split skin autograft alone.
Study: NCT06160219

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydroxycobalamin
Description: prophylactic use of hydroxycobalamin in vasoplegia in high risk patients undergoing cardiac surgeries

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxycobalamin
Description: prophylactic use of hydroxycobalamin in vasoplegia in high risk patients undergoing cardiac surgeries
Study: NCT01287026

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac Real-time MRI RHC (Right Heart Catheterization)
Study: NCT02760745

Intervention type: OTHER
Intervention: Ancillary tests
Description: Blood culture, complete blood count, crp, urinalysis for all patients. If clinically indicated: Urine culture, chest x ray, csf culture, stool culture, joint fluid culture

Intervention type: OTHER
Intervention: Ancillary tests
Description: Blood culture, complete blood count, crp, urinalysis for all patients. If clinically indicated: Urine culture, chest x ray, csf culture, stool culture, joint fluid culture
Study: NCT02570594

Intervention type: OTHER
Group type: OTHER
Intervention: questionary
Study: NCT00898287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P276-00
Description: Subjects will be enrolled at different levels of P276-00 dosage as follows:- Level 1 - 100mg/ m 2/day x 5 q 3 weeks Level 2 - 140 mg/ m2/day x 5 q 3 weeks Level 3 - 185 mg/ m2 /day x 5 q 3 weeks P276-00 will be administered as intravenous infusion in 200 ml of 5% dextrose over 30min from days 1 to 5 per 21 day cycle. Six such cycles will be administered unless there is progression of disease or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered as an intravenous infusion at dose of 1000mg/m 2 over 30 mins every week for 7 weeks followed by a gap of one week and then 3 weekly doses every 4 weeks. This treatment will be continued for six P276-00 cycles of 3 weeks each unless there is progression of disease or unacceptable toxicity.
Study: NCT01062347

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zinc
Study: NCT02480348

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polymer-free DES (Drug Eluting Stent)
Study: NCT03936595

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core exercises protocol
Description: Participants will perform:~1. Squats, 4 sets of 5 repetitions at 60% 1RM~2. Deadlifts, 4 sets of 5 repetitions at 60% 1RM~3. Lunges, 4 sets of 5 repetitions at 60% 1RM~4. Step ups, 4 sets of 5 repetitions at 60% 1RM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structural exercises protocol
Description: Participants will perform:~1. Snatch, 4 sets of 5 repetitions at 60% 1RM~2. Hang clean, 4 sets of 5 repetitions at 60% 1RM~3. Push jerk, 4 sets of 5 repetitions at 60% 1RM~4. Split push jerk, 4 sets of 5 repetitions at 60% 1RM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accentuated eccentric load exercises protocol
Description: Participants will perform:~1. Deadlifts - squat jump, 4 sets of 5 repetitions at 30% body mass (BM)~2. Step down - squat jump, 4 sets of 5 repetitions at 30% BM~3. Step down - lunges, 4 sets of 5 repetitions at 30% BM~4. Hip thrusts, 4 sets of 5 repetitions at 30% BM

Intervention type: OTHER
Group type: OTHER
Intervention: Control condition
Description: Participants will perform all the measurements that are comprised in the experimental conditions without performing any exercise protocol
Study: NCT04409314

Intervention type: DRUG
Intervention: Fluorine F 18-fluoroazomycin Arabinoside
Description: Given IV

Intervention type: PROCEDURE
Intervention: Positron Emission Tomography
Description: Undergo PET scan
Study: NCT02759692

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TEST Contact Lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TEST Contact Lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CONTROL Contact Lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CONTROL Contact Lens
Study: NCT03490656

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI Scan - in addition to standard of care
Description: Up to 3 Tesla (T) MRI

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI Scan - not in addition to standard of care
Description: Up to 3 Tesla (T) MRI
Study: NCT01434810

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Filtered-sunlight phototherapy
Description: Infants will receive six hours per day of filtered-sunlight phototherapy for 1 to 10 days. The filtering will be done using window tinting film. Window tinting films by Solutia, Inc., and V-KOOL, Inc.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional phototherapy
Description: Infants will receive six hours per day of conventional phototherapy for 1 to 10 days.
Study: NCT00791895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 30
Description: Treat-to-target dose titration scheme
Study: NCT04144361

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sleeve with plication
Description: sleeve with plication

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sleeve without plication
Description: sleeve without plication
Study: NCT01059786

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: Corticosteroids should be available for immediate use in the event of a hypersensitivity reaction to Rituximab.
Study: NCT05173857

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Advance PTX
Description: PTA in Dysfunctional Haemodialysis Access

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Advance LP (Low Profile)
Description: Plain Old Balloon Angioplasty (POBA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel (PTX)
Description: Paclitaxel (PTX)
Study: NCT04462887

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nursing intervention program
Description: The intervention consisted of structured information (SI) provided in a booklet, nursing telephone support (NTS) and access to a nurse pager 24h/day. The SI booklet, Sudden Cardiac Arrest: A Survivor's Experience, contains 2 components: a descriptive component including individual verbatim statements about experiences of others during the first year of recovery and a management component outlining successful strategies used by others in dealing with issues in recovery. The NTS telephone calls included: check-in about current concerns, assessment of the topic for the week, review of common recovery experiences, discussion of behavioral strategies for dealing with the topic for the week, provision of positive feedback for strategies already working well, anxiety reduction statements, practice of new behaviors using role-playing and problem solving techniques, summarization, setting specific goals for the upcoming week, and collaborating on a learning assignment for the subsequent week.
Study: NCT03951324

Intervention type: OTHER
Intervention: Interobserver agreement or Interrater agreement
Description: Interobserver agreement or Interrater agreement using 9 visual criteria for diagnosing VLE clips that feature indeterminate biliary or pancreatic duct strictures

Intervention type: OTHER
Intervention: Interobserver agreement or Interrater agreement
Description: Interobserver agreement or Interrater agreement using 9 visual criteria for diagnosing VLE clips that feature indeterminate biliary or pancreatic duct strictures
Study: NCT02607267

Intervention type: OTHER
Intervention: LSG and LRYGB
Description: The role of the Edmonton Obesity Staging System in predicting post-operative outcome and 30-day mortality after metabolic surgery (LSG and LRYGB)

Intervention type: OTHER
Intervention: LSG and LRYGB
Description: The role of the Edmonton Obesity Staging System in predicting post-operative outcome and 30-day mortality after metabolic surgery (LSG and LRYGB)
Study: NCT04962386

Intervention type: DRUG
Intervention: Hormone replacement therapy
Description: HRT women were treated with an estrogen-progesterone combination therapy packaged with estradiol tablets/estradiol and dynamic progesterone (Abbott Health Products BV, Weesp, the Netherlands).Take this medicine once a day.A course of treatment was defined as 28 days of continuous treatment.One white tablet containing 1mg of estradiol was taken daily for the first 14 days and one gray tablet containing 1mg of estradiol and 10 mg of dynamic progesterone was taken daily for the remaining 14 days.

Intervention type: DRUG
Intervention: Hormone replacement therapy
Description: HRT women were treated with an estrogen-progesterone combination therapy packaged with estradiol tablets/estradiol and dynamic progesterone (Abbott Health Products BV, Weesp, the Netherlands).Take this medicine once a day.A course of treatment was defined as 28 days of continuous treatment.One white tablet containing 1mg of estradiol was taken daily for the first 14 days and one gray tablet containing 1mg of estradiol and 10 mg of dynamic progesterone was taken daily for the remaining 14 days.
Study: NCT01499433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caspofungin
Description: Caspofungin injection, intravenously administered, loading dose at 70mg qd for the first 24hrs, maintenance dose at 50mg qd for the following 20 days
Study: NCT04550923

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Z-Brace interbody fusion device
Description: Use non-rigid (Titanium Alloy, Z-Brace, Baui Biotech) interbody fusion device in Anterior Cervical Discectomy and Fusion (ACDF) surgery

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: PEEK interbody fusion device
Description: Use rigid (PEEK) interbody fusion device in Anterior Cervical Discectomy and Fusion (ACDF) surgery
Study: NCT04617912

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Long AFOV PennPET Explorer
Description: A long-axial field-of-view (LAFOV) time-of-flight PET scanner, developed at the University of Pennsylvania, being tested for real-world applications.
Study: NCT01509014

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CPATCH intervention to support statin adherence
Description: Routine identification of new statin users (first year of therapy), consistent assessment of barriers to adherence at every dispensation for these patients, reassurance about efficacy and safety, and proactive response to identified adherence barriers.
Study: NCT01792687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARN-509
Description: Dose-escalation: 120 milligram (mg), 180 mg, 240 mg, oral, daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: 1,000 mg, oral, daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg, oral, daily
Study: NCT03931525

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractitional Radiofrecuency with Drug Delivery
Description: Electromagnetic energy within the spectrum of radio frequencies applied to the skin whose purpose is to generate thermal effects and which will be complemented with a skin drug

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractitional Radiofrecuency with Drug Delivery
Description: Electromagnetic energy within the spectrum of radio frequencies applied to the skin whose purpose is to generate thermal effects and which will be complemented with a skin drug

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractitional Radiofrecuency
Description: Electromagnetic energy within the spectrum of radio frequencies applied to the skin whose purpose is to generate thermal effects

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractitional Radiofrecuency
Description: Electromagnetic energy within the spectrum of radio frequencies applied to the skin whose purpose is to generate thermal effects
Study: NCT00618332

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mometasone furoate nasal spray
Description: 2 puffs in each nostril once a day for 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 puffs in each nostril once a day for 2 weeks
Study: NCT00436865

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Weight loss

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Weight loss
Study: NCT04191499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inavolisib
Description: Participants will receive oral inavolisib on Days 1-28 of each 28-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive oral placebo on Days 1-28 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Participants will receive oral palbociclib on Days 1-21 of each 28-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Palbociclib
Description: Participants will receive oral palbociclib on Days 1-21 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Participants will receive intramuscular (IM) fulvestrant approximately every 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant
Description: Participants will receive intramuscular (IM) fulvestrant approximately every 4 weeks.
Study: NCT03868774

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Description: rTMS is a new non-invasive antidepressant method, which implies non-convulsive focal stimulation of the prefrontal cortex of the brain through a time varying magnetic field.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Description: rTMS is a new non-invasive antidepressant method, which implies non-convulsive focal stimulation of the prefrontal cortex of the brain through a time varying magnetic field.
Study: NCT03807596

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal treatment with Hyaluronic acid associated with SRP
Description: In addition to SRP, patients in the test group received adjunct subgingival application of hyaluronic acid in all selected periodontal pockets.
Study: NCT01129687

Intervention type: PROCEDURE
Intervention: Microsurgery
Description: Patient would under to total, near-total, or subtotal resection of tumor

Intervention type: PROCEDURE
Intervention: Stereotactic radiation therapy
Description: Patient who has sign of growth of tumor remnant would undergo this treatment
Study: NCT03807596

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling & root planning alone
Description: Patients received full-mouth supra- \& sub-gingival SRP with the use of ultrasonic device \& periodontal universal \& Gracey curettes under local anesthesia.
Study: NCT02116075

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural Prolotherapy
Description: caudal injection of 10mL 5% dextrose

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Steroid
Description: caudal injection of 1mL 80mg depo-medrol with 9ml of 1% lidocaine
Study: NCT02988713

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Programming
Description: Programming spinal cord stimulation (SCS) in patients undergoing a Boston Scientific (BSC) spinal cord stimulation (SCS) temporary trial
Study: NCT02304757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99Tc-MDP
Description: 99Tc-MDP, H20000218

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosamax
Description: H20080172
Study: NCT02541318

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Duo-in exercise
Description: Duo-in exercise was originated from China and with a 5000-years history. Ancient people adopted Duo-in to treat and prevent diseases.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Duo-in exercise
Description: Duo-in exercise was originated from China and with a 5000-years history. Ancient people adopted Duo-in to treat and prevent diseases.